Loading…
Volitionrx Ltd
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in VNRX.
▼ -99.6% over 5Y.
today you would have $4.18▼ -99.6%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $5.20 | $12.00 | $14.40 | $48.60 | |
| P/S | 61.4x | 18.9x | 46.7x | 76.1x | 459.0x |
| EPS | -$4.40 | -$6.20 | -$10.00 | -$11.00 | |
| Profit margin | -3370.90% | -1352.16% | -2186.27% | -4555.53% | -9879.11% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| BMRABiomerica Inc | $2.14 | — | 2.0x | — | -94.32% | $6.61M |
| DRMADermata Therapeutics, Inc. | $1.34 | — | 1.5x | — | -183.89% | $6.64M |
| HCWBHCW Biologics Inc. | $3.43 | — | 0.7x | — | -151.36% | $6.3M |
| SNOASonoma Pharmaceuticals, Inc. | $1.31 |
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
Company description provided by Yahoo Finance.
| — |
| 0.8x |
| — |
| -42.52% |
| $6.27M |
| CLGNCollPlant Biotechnologies Ltd | $0.36 | — | 1.1x | — | -151.99% | $6.77M |
| ACXPAcurx Pharmaceuticals, Inc. | $1.44 | — | 0.8x | — | -128.11% | $6.19M |